Know the medication in advance: What does adagrasib treat?

Adagrasib (Adagrasib) is a small molecule inhibitor of KRAS G12C, indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations. Adagrasiib is a targeted therapy that inhibits KRAS G12C to inhibit tumor growth in patients with KRAS G12C-mutant non-small cell lung cancer who have spread to other parts of the body or cannot be removed by surgery and have received at least one prior treatment.

Adagrasibis available astabletsorally, twice daily, with or without food. Warnings and precautions related to adagrasib include gastrointestinal adverse reactions, QTc interval prolongation, hepatotoxicity, and interstitial lung disease/pneumonitis. Common adverse reactions include nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, and decreased appetite. Common laboratory abnormalities include lymphopenia, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, leukopenia, neutropenia, and increased alkaline phosphatase.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.